MedTrace Logo

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

NCT06422624 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-05-22

No results posted yet for this study

Summary

The purpose of the trail is to evaluate the safety, tolerability and pharmacokinetics of a single escalated doses of semaglutide extended-release injectable suspension in healthy adult, human study participants under fasting condition.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide Extended-release for Injectable Suspension, 1 mg

Singel-dose; Subcutaneous

DRUG

Semaglutide Extended-release for Injectable Suspension, 4 mg

Singel-dose; Subcutaneous

DRUG

Semaglutide Extended-release for Injectable Suspension, 8 mg

Singel-dose; Subcutaneous

Sponsors & Collaborators

  • Bostal Drug Delivery Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-31
Primary Completion
2024-11-30
Completion
2024-11-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06422624 on ClinicalTrials.gov